Lipocine (LPCN) EPS (Basic) Growth (1y) (2013 - 2025)
Lipocine (LPCN) EPS (Basic) Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | -16.29% |
| 10 | Lipocine | 11.42 Mn | -12.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -41.90% |
| Jun 30, 2025 | 28.23% |
| Mar 31, 2025 | -152.75% |
| Dec 31, 2024 | 177.08% |
| Sep 30, 2024 | 66.99% |
| Jun 30, 2024 | 15.29% |
| Mar 31, 2024 | 188.91% |
| Dec 31, 2023 | -1.05% |
| Sep 30, 2023 | -171.58% |
| Jun 30, 2023 | -34.08% |
| Mar 31, 2023 | -10.72% |
| Dec 31, 2022 | -117.36% |
| Sep 30, 2022 | 22.00% |
| Jun 30, 2022 | 61.44% |
| Mar 31, 2022 | 3.98% |
| Dec 31, 2021 | 279.25% |
| Sep 30, 2021 | 47.54% |
| Jun 30, 2021 | 39.74% |
| Mar 31, 2021 | 70.53% |
| Dec 31, 2020 | 36.31% |